Literature DB >> 3490908

Modulation of cell growth, differentiation, and production of interleukin-3 by 1 alpha,25-dihydroxyvitamin D3 in the murine myelomonocytic leukemia cell line WEHI-3.

J Abe, Y Moriya, M Saito, Y Sugawara, T Suda, Y Nishii.   

Abstract

The effect of 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2D3], the active form of vitamin D3, on the relation between cell growth and differentiation was examined in a murine myelomonocytic leukemia cell line WEHI-3 which is known to produce high levels of interleukin-3. 1 alpha,25(OH)2D3 markedly inhibited proliferation of WEHI-3 cells in a time- and dose-dependent manner. Flow cytometric analysis of the cell cycle by a double staining method using fluorescein isothiocyanate-conjugated anti-bromodeoxyuridine and propidium iodide revealed that 1 alpha,25(OH2D3 increased the proportion and the number of cells accumulating in the G0-G1 phase and decreased those in the S phase. The phenotype of the surface antigens of the cells was of the T-cell lineage, but the cells became positive in macrophage-associated surface markers (Mac-1 and Ia) after treatment with 1 alpha,25(OH)2D3. The vitamin induced phagocytic activity, appearance of Fc receptors, nitroblue tetrazolium-reducing activity, and nonspecific esterase activity, indicating that the vitamin induces the cells to differentiate into macrophages. Furthermore, 1 alpha,25(OH)2D3 inhibited interleukin-3 production by the cells in a time- and dose-dependent manner. These results suggest that 1 alpha,25(OH)2D3 inhibits proliferation of WEHI-3 cells by blocking transition of the cells from the G0-G1 to the S phase, resulting in induction of the G0-G1-arrested cells to differentiate into macrophages. The relation between the suppression by 1 alpha,25(OH)2D3 of cell growth and interleukin-3 production remains to be elucidated in the future.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490908

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog.

Authors:  K Takeyama; Y Masuhiro; H Fuse; H Endoh; A Murayama; S Kitanaka; M Suzawa; J Yanagisawa; S Kato
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

2.  The requirement for and changing composition of the activating protein-1 transcription factor during differentiation of human leukemia HL60 cells induced by 1,25-dihydroxyvitamin D3.

Authors:  Xuening Wang; George P Studzinski
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

3.  1 alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.

Authors:  Y Iino; M Yoshida; N Sugamata; M Maemura; S Ohwada; T Yokoe; T Ishikita; R Horiuchi; Y Morishita
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Human c-fgr induces a monocyte-specific enzyme in NIH 3T3 cells.

Authors:  K Inoue; B Wongsasant; T Akiyama; K Toyoshima
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

5.  Vitamin D status and breast cancer in Saudi Arabian women: case-control study.

Authors:  Fatimah M Yousef; Elizabeth T Jacobs; Paul T Kang; Iman A Hakim; Scott Going; Jehad M Yousef; Rajaa M Al-Raddadi; Taha A Kumosani; Cynthia A Thomson
Journal:  Am J Clin Nutr       Date:  2013-05-22       Impact factor: 7.045

Review 6.  Vitamin D in prostate cancer.

Authors:  Donald L Trump; Jeanny B Aragon-Ching
Journal:  Asian J Androl       Date:  2018 May-Jun       Impact factor: 3.285

Review 7.  Vitamin D and Cancer: An Historical Overview of the Epidemiology and Mechanisms.

Authors:  Alberto Muñoz; William B Grant
Journal:  Nutrients       Date:  2022-03-30       Impact factor: 5.717

Review 8.  Vitamin D in inflammatory diseases.

Authors:  Thea K Wöbke; Bernd L Sorg; Dieter Steinhilber
Journal:  Front Physiol       Date:  2014-07-02       Impact factor: 4.566

9.  Calcitriol and cancer therapy: A missed opportunity.

Authors:  Donald L Trump
Journal:  Bone Rep       Date:  2018-06-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.